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associated with elevation of serum
carcinoembryonic antigen levelYasutaka Hayashido *, Yukio Yoshioka, Tomoaki Shintani,
Tomoaki Hamana, Koh-ichi Koizumi, Yasutaka Ishida, Tetsuji OkamotoDepartment of Molecular Oral Medicine and Maxillofacial Surgery, Division of Frontier Medical Science,
Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku,
Hiroshima 734-8553, JapanReceived 28 June 2005; accepted 29 June 2005Summary Primary intraosseous squamous cell carcinoma (SCC) is a rare malignant
tumor of the jaw. We report a case of intraosseous SCC involving the mandible of a
60-year-old male. The serum level of carcinoembryonic antigen (CEA) was exceed-
ingly elevated. Immunohistochemical analysis showed that the tumor was strongly
stained with anti-CEA antibody. The patients underwent wide surgical excision of
the tumor, and serum CEA level gradually decreased and remained in the normal
range. Serum CEA level increased 37 months after tumor resection, and radical neck
dissection was performed because of lymphadenopathy. The serum level of CEA cor-
related well with the clinical course of present tumor and was useful in monitoring











Primary intraosseous carcinoma (PIOC) is a rare
squamous cell carcinoma (SCC) arising within the
jaw, which has no initial connection with the oral
mucosa, overlying skin, or antral or nasal mucosa.1
The tumor was first described as central epidermoid741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights rese
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odontogenic carcinoma because it is considered to
develop from the epithelium involved in odontogen-
esis.3 The WHO classification of PIOC includes carci-
nomas arising de novo, carcinomas arising from an
ameloblastoma or an exoodontogenic cyst.1
Serial measurement of serum tumor markers has
been well known to be useful to evaluate the ther-
apeutic result and detect relapse in various can-
cers. While overexpression of carcinoembryonic
antigen (CEA) is well recognized in gastrointestinal
carcinoma, expression of CEA in head and neckrved.
268 Y. Hayashido et al.cancer is not widely recognized and has received
little attention.
In this article, we report a case of PIOC of
the mandible with elevated serum CEA level, and
discuss the surgical management and the useful-
ness of CEA in monitoring the treatment and
relapse.Case report
A 70-year-old Japanese man was referred to
Hiroshima University Dental Hospital because of
pain and swelling in the anterior region of the man-
dible. Oral examination revealed an expansile mass
in the alveolar process of the anterior mandible,
which was covered with normal mucosa (Fig. 1A).
The tumor was approximately 60 · 28 mm in its
greatest dimensions. Panoramic radiography
showed an ill-defined radiolucency expanding in
the anterior mandible, which associated with an
embedded canine in the center (Fig. 1B). Computed
tomography (CT) scan of the head and neck re-
vealed a large mass with bone destruction of the
mandible (Fig. 1C). Serum levels of several tumor
markers were examined. Serum CEA level was
markedly elevated. None of the serum levels of
SCC antigen, Ca19-9, CA125, a-fetoprotein (AFP),
protein induced by vitamin K absence or antago-
nists-II (PIVKA-II) and prostatic specific antigen
(PSA) was elevated. These findings suggested thatFigure 1 (A) Intraoral photograph showing a diffuse swelli
examination. (B) Panoramic radiography showing an ill-define
embedded canine in the center. (C) CT scan showing a largethe tumor was PIOC or malignant mesenchymal
tumor as well as metastatic tumor. Thoracic and
abdomen CT showed no tumoral lesions. Gallium
scintigraphy demonstrated no areas of increased
radioactivity except the mandible. The incisional
biopsy of the tumor was performed under local
anesthesia, and the specimen was stained with
hematoxylin and eosin. Histopathological exam-
ination exhibited that the tumor consisted of malig-
nant squamous cells with bright eosinophilic
cytoplasm and hyperchromatic nucleus, which
formed lumina containing eosinophilic mucous
materials. The oral mucosa overlying the tumor
was normal and did not seem to be connected with
the tumor (Fig. 2A). Moreover, intracytoplasmic lu-
mina were frequently observed. Mitotic figures, nu-
clear atypism and pleomorphism were occasionally
observed (Fig. 2B). Immunohistochemical examina-
tion showed that the tumor cells and eosinophilic
mucous materials in the lumina were strongly
stained with anti-CEA antibody (Fig. 2C). Finally,
we concluded that the tumor was a primary intra-
osseous poorly differentiated SCC with adenoma-
tous metaplasia. CEA in the serum was considered
to derive from the tumor. The patient underwent
composite resection of the mandible associated
with bilateral suprahyoid neck dissection. Subse-
quently, reconstruction was performed with tita-
nium mandibular reconstruction plate. As shown
in Fig. 3, serum CEA level of gradually decreased
and remained in the normal range 6 months afterng with no ulceration in the anterior mandible at initial
d osteolytic lesion in the mandibular body associated with
mass in the mandible with bone destruction.
Figure 2 (A) Photomicrograph of the biopsy specimen showing poorly differentiated squamous cell carcinoma with
the formation of lumina containing eosinophilic mucous materials and the overlaying oral mucosa was normal without
connection with tumor (hematoxylin–eosin stain, original magnification A: ·25). (B) Intracytoplasmic lumina were
frequently observed. Hyperchromatic or pleomorphic nuclei and mitoses are occasionally observed (hematoxylin–
eosin stain, original magnification B: ·62). (C) Tumor cells and mucous materials in the lumina showed strong
immunoreactivity for CEA (streptavidin–biotin technique, original magnification C: ·80).
Primary intraosseous carcinoma 269the surgery. However, serum CEA level gradually
increased 37 months after the initial operation.
CT scan of the head and neck revealed the right
cervical lymphadenopathy, and the patient under-
went right radical neck dissection. After radicalneck dissection, the serum level of CEA decreased
again. No sign of local recurrence or distant metas-
tasis was noted 7 months after the secondary surgi-
cal procedure and CEA level remained in the
normal range.
Figure 3 Serum CEA level during a 48-month follow-up.
CEA level was markedly elevated before treatment, and
rapidly decreased after the initial operation. Lymphad-
enopathy and the elevation of CEA 37 months after the
initial operation were observed. After radical neck
dissection, CEA decreased again. Dotted lines show
normal value of CEA (0.8–5.9 ng/ml).
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PIOC is a rare neoplasm arising from residues of
odontogenic epithelium in the jaw bone.3 Accord-
ing to WHO classification, the tumors are sub-
classed into as follows: carcinoma arising de
novo, carcinomas arising from ameloblastoma or
odontogenic cyst.1 The present tumor was associ-
ated with an embedded canine in the center,
although any cystic components and other odonto-
genic tumor cells were not observed. Therefore,
the tumor might be poorly differentiated SCC aris-
ing from pre-existing odontogenic cyst.
Treatment for PIOC is principally wide local
resection, and radiotherapy and chemotherapy
may be performed with adjunctive treatments. Its
prognosis is relatively poor, and the 5-year survival
rate ranges from 30% to 40%.4–6 In the present
case, the patient underwent wide surgical excision
of the tumor accompanied with bilateral suprahy-
oid neck dissection. No additional treatment was
performed because the tumor was surgically ex-
cised with appropriate surgical margin. PIOC occa-
sionally associates with the metastasis to the
regional lymph nodes.7,8. No regional metastasis
was observed at the initial examination of the pres-
ent tumor. However, lymphadenopathy was ob-
served 37 months after the tumor resection, and
additional radical neck dissection was performed.
Serum tumor markers have been used in clinical
oncology for screening, diagnosis, prognosis, and
monitoring treatment and possible relapse. Clinical
findings at the initial examination suggested thatthe present tumor might be metastatic lesion as
well as primary malignant neoplasm such as central
carcinoma of the mandible. Several tumor markers
including CEA, SCC antigen, CA19-9, CA125, AFP,
PIVKA-II and PSA were examined. Serum CEA level
was markedly elevated and other tumor makers
were not elevated. CEA, an oncofetal glycoprotein
is well known to overexpress in gastrointestinal
adenocarcinoma. The overexpression of CEA sug-
gested that the tumor of the mandible might be
metastatic tumor from other sites such as gastroin-
testinal tract. However, thoracic and abdominal
CT, and isotope scintigraphy did not show any tu-
moral lesions except the tumor of the mandible.
The biopsy specimen was poorly differentiated
SCC, and showed strong immunoreactivity for
CEA. Therefore, we concluded that the present
tumor was primary intraosseous SCC and CEA in
the serum was produced by the tumor. Several
studies have shown that CEA overexpresses in 15–
30% of oral cancers and SCC antigen is not elevated
in about 50% of head and neck SCCs.9–11 The pres-
ent intraosseous SCC was associated with ade-
nomatous metaplasia such as the formation of
lumina containing eosinophilic mucous materials
and intracytoplasmic lumina, which might contrib-
ute to the excessive production of CEA. Strong
immunoreactivity for CEA was observed in the tu-
mor cells forming the lumina and eosinophilic mu-
cous materials in the lumina. The serum level of
CEA decreased after tumor resection, and was ele-
vated in parallel with cervical lymphadenopathy
after the initial operation. Serum CEA level was
well related with the process of the treatment
and relapse in the present tumor. CEA might be a
useful marker in monitoring the clinical course in
the present tumor.References
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